Navigation Links
Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohn's Disease and Ulcerative Colitis in the United States
Date:6/21/2013

estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors are cautioned not to unduly rely on such forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding Takeda's business, including general economic conditions in Japan, the United States and worldwide; (2) competitive pressures and developments; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) actions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates in development; and (8) integration activities with acquired companies.

The forward-looking statements contained in this press release speak only as of the date of this press release, and Takeda undertakes no obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If Takeda does update or correct one or more of these statements, investors and others should not conclude that Takeda will make additional updates or corrections.


'/>"/>
SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
2. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
3. Takeda to Acquire Inviragen, Inc.
4. Takeda Responds to Verdict in Diabetes Drug Case
5. Takeda Launches New Subsidiary in Ecuador
6. Takeda lanza nueva subsidiaria en Ecuador
7. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
8. Takeda presenta la richiesta di autorizzazione allimmissione in commercio nellUnione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
9. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
10. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
11. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Luoxis Diagnostics, Inc. , a ... MKT: AMPE), today announced an upcoming presentation at ... American Academy of Surgical Trauma (AAST) and Clinical ... Philadelphia, Pennsylvania that will be held ... from a recently completed five-year prospective clinical trial ...
(Date:8/19/2014)... , August 19, 2014 ,Weight ... Pipeline Assessment, 2014, report provides comprehensive insights about phase ... A key objective of the report is to establish ... III pipeline drugs across the different countries and regions. ... thoroughly, the report also provides details on the drug ...
(Date:8/18/2014)... Gamida Cell , a world ... today that it has signed an investment and option agreement ... Novartis " ) . According to the agreement, ... return will receive 15% equity and an option to fully ... period of time following achievement of certain milestones connected to ...
Breaking Medicine Technology:Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 2Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 3Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 4
... - Both co-primary endpoints, Wake After Sleep Onset and ... Sleep, were met at both doses - Evotec to ... 10am EST) today , HAMBURG, Germany | OXFORD, England, ... today positive top-line,results from its first phase II clinical ...
... Summary: Follow-up RAS data presented at ASCO , ... gave,a presentation titled "RAS peptide vaccination in resected,pancreatic ... long term survival" at ASCO's (American Society of ... of 23 resected pancreatic cancer patients,immunized in the ...
Cached Medicine Technology:Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 2Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 3Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 4Pharmexa A/S (DK) - Long lasting immune response and survival to,RAS vaccine 2
(Date:8/20/2014)... “Have you recently been involved in an auto ... lawyer serving the greater Seattle area. “Are you still feeling ... keep reading . , In a recently released article, Dax ... accident can use to see if they may qualify for ... insurance claim will allow an individual to receive medical treatment ...
(Date:8/20/2014)... August 20, 2014 Low market concentration, ... availability of substitutes typify the market for packaging design ... 3.1 out of 5, indicating a moderate level of ... and suppliers have an equal amount of leverage during ... , First, few substitutes exist for packaging design ...
(Date:8/20/2014)... First Choice Emergency Room , the ... United States, named Richard Daniels, DO the Medical Director ... , “We are pleased to announce that Dr. Daniels ... facility in Pflugerville,” said Dr. James M. Muzzarelli, Executive ... Dr. Daniels received his undergraduate degree from Brigham Young ...
(Date:8/20/2014)... 2014 Kowa Optimed returns after a ... debut the new SL-17 portable slit lamp. , The ... LED source controlled by an illuminated thumb wheel for ... uses commercially available AAA rechargeable and dry cell batteries, ... requiring batteries designed specifically for the device. The new ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 This ... line of software defined networking, high availability cloud ... portfolio of Resellers, while allowing OPEN-V to sell ... is pleased to work with OPEN-V on this ... Donald Hows, manager distribution channels at storageFOUNDRY. "Nautilus ...
Breaking Medicine News(10 mins):Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 4Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3
... 40 million Needy Children and Adults to be Affected Nationwide, Study ... ... A survey released today,by Spectrum Science Communications states that a little known,anti-privatization ... administer its Medicaid program. The,measure, offered as an amendment to the House-passed ...
... afflicted humans, primate ancestors , , FRIDAY, Feb. 29 (HealthDay News) ... as protection against a group of viruses that includes HIV ... that their finding suggests the current AIDS epidemic is not ... in Asian macaques is a hybrid of two existing proteins, ...
... Openings to Feature Cincinnati Reds Great, Doug Flynn, and Pitching ... ... RICHEY, Fla., Feb 29 Zounds,Hearing, a unique manufacturing and retail ... professional,service, opened its doors recently in the Westfield Sarasota Square Mall,(Sarasota) ...
... of Health Professionals Finds Acute Shortage of ... MILPITAS, Calif., Feb. 29 With mounting evidence that,many ... the,nation,s growing epidemic of diabetes, the Johnson & Johnson ... the U.S. to,improve how practitioners deliver diabetes care in ...
... lung cancer, according to a study of more than ... increase the risk of developing it. , Our study ... did not show any evidence for a decreased risk ... Slatore, M.D., of the University of Washington, in Seattle. ...
... diseases like chronic bronchitis, but genes also play a ... Sweden, who studied more than 40,000 Swedish twins to ... each play a role ion the development of chronic ... genetic component and smoking is a primary risk factor ...
Cached Medicine News:Health News:Farm Bill Provision Will Disrupt Arkansas Medicaid Program 2Health News:Farm Bill Provision Will Disrupt Arkansas Medicaid Program 3Health News:Monkey Gene That Blocks AIDS Viruses Evolved More Than Once 2Health News:Zounds! - Sarasota and Port Richey 'Hear' New Retail Concept Coming 2Health News:Zounds! - Sarasota and Port Richey 'Hear' New Retail Concept Coming 3Health News:Johnson & Johnson Diabetes Institute, LLC Launches New Center to Provide State-of-the-Art Education, Training to Health Professionals 2Health News:Johnson & Johnson Diabetes Institute, LLC Launches New Center to Provide State-of-the-Art Education, Training to Health Professionals 3Health News:Johnson & Johnson Diabetes Institute, LLC Launches New Center to Provide State-of-the-Art Education, Training to Health Professionals 4Health News:Johnson & Johnson Diabetes Institute, LLC Launches New Center to Provide State-of-the-Art Education, Training to Health Professionals 5Health News:Certain vitamin supplements may increase lung cancer risk, especially in smokers 2Health News:Genetic factors in smoking also increase risk of chronic bronchitis 2
... MJS anatomic knee ... enhance durability, minimize polyethylene ... surfaces, to minimize contact ... and to achieve a ...
Simplified Design-Based on 15 Years of Experience...
... The result of more than a ... is based on a comprehensive study of ... resection, and tibial insert retrieval analysis.,As a ... axial rotation and motion patterns in total ...
... True to its leadership role within ... the clinical experience of the industry's leading ... Platform Knee System, with the clinically proven ... world's leading rotating platform knee. ,The result ...
Medicine Products: